Page 170 - Haematologica Vol. 110 - January 2025

ARTICLE - Targeted CDK7 and BRD4 inhibition in myeloma
Y. Yao et al.
effects in head and neck squamous cell carcinoma. Cancer Lett.
2020;469:510-523.
25. Choudhury SR, Ashby C, Tytarenko R, et al. The functional
epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020;13(1):108.
26. Cardona-Benavides IJ, de Ramon C, Gutierrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells. 2021;10(2):336.
27. Xie Z, Bi C, Chooi JY, Chan ZL, Mustafa N, Chng WJ. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib. Leukemia. 2015;29(12):2347-2354.
28. Tiedemann RE, Mao X, Shi CX, et al. Identification of kinetin
riboside as a repressor of CCND1 and CCND2 with preclinical
antimyeloma activity. J Clin Invest. 2008;118(5):1750-1764.
29. Jovanovic KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel
B, Manier S. Targeting MYC in multiple myeloma. Leukemia.
2018;32(6):1295-1306.
30. Arora M, Moser J, Hoffman TE, et al. Rapid adaptation to CDK2
inhibition exposes intrinsic cell-cycle plasticity. Cell.
2023;186(12):2628-2643.e21.
31. Ge JY, Shu S, Kwon M, et al. Acquired resistance to combined
BET and CDK4/6 inhibition in triple-negative breast cancer.
Nat Commun. 2020;11(1):2350.
32. Ding D, Zheng R, Tian Y, et al. Retinoblastoma protein as an
intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. Nat Commun. 2022;13(1):6311.
Haematologica | 110 January 2025
162